Mary Wu and colleagues1 suggest a change to WHO s COVID-19 treatment guidelines for
monoclonal antibodies. These living guidelines were updated on Sept 16, 2022, with
strong recommendations against the use of sotrovimab and casirivimab–imdevimab following
the emergence of new SARS-CoV-2 variants and subvariants.2 We, as members of the WHO
panel responsible for presenting the evidence to the Guideline Development Group (GDG),
welcome this opportunity to elaborate on the evidence considered during the GDG meeting.